OTSUKA PHARMACEUTICAL CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.otsuka.co.jp

Clinical Trials

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Phase 3

Completed

Conditions: Cardiac Edema

Interventions: Drug: OPC-41061(Tolvaptan)
Drug: Placebo

First Posted Date: 2007-09-05

Last Posted Date: 2013-12-25

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT00525265

A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: OPC-18
Drug: cisplatin

First Posted Date: 2007-09-03

Last Posted Date: 2015-10-15

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT00524498

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Phase 2

Completed

Conditions: Pain Due to Osteoporosis

Interventions: Drug: OPC-249

First Posted Date: 2007-07-20

Last Posted Date: 2014-01-30

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 101

Registration Number: NCT00504426

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Phase 2

Completed

Conditions: Cirrhosis

Interventions: Drug: OPC-41061 15mg
Drug: OPC-41061 placebo
Drug: OPC-41061 7.5mg
Drug: OPC-41601 30mg

First Posted Date: 2007-05-28

Last Posted Date: 2014-03-14

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT00479336

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: placebo
Drug: 1% OPC-12759 ophthalmic suspension
Drug: 2% OPC-12759 ophthalmic suspension

First Posted Date: 2007-05-21

Last Posted Date: 2013-06-13

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 308

Registration Number: NCT00475319

An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: rebamipide

First Posted Date: 2007-04-20

Last Posted Date: 2021-07-20

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 124

Registration Number: NCT00463151

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Phase 3

Completed

Conditions: Edema, Cardiac

Interventions: Drug: OPC-41061(Tolvaptan)

First Posted Date: 2007-04-19

Last Posted Date: 2014-02-04

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT00462670

Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2006-10-25

Last Posted Date: 2014-02-12

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 111

Registration Number: NCT00392197

A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn Disease

First Posted Date: 2006-04-24

Last Posted Date: 2021-02-15

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 29

Registration Number: NCT00317369

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Phase 2

Terminated

Conditions: Colitis, Ulcerative

First Posted Date: 2006-04-24

Last Posted Date: 2021-04-30

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 43

Registration Number: NCT00317356

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy